{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:23:23Z","timestamp":1760909003513,"version":"3.41.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bulcan.2016.01.020","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T17:54:23Z","timestamp":1456682063000},"page":"499-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["N\u00e9phrotoxicit\u00e9 du l\u00e9nalidomide"],"prefix":"10.1016","volume":"103","author":[{"given":"Rania","family":"Kheder El-Fekih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2016.01.020_bib0265","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14656561003645611","article-title":"Lenalidomide in multiple myeloma: current role and future directions","volume":"11","author":"Zeldis","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.bulcan.2016.01.020_bib0280","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2010.02.013","article-title":"Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions","volume":"24","author":"Komrokji","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0285","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.23722","article-title":"Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis","volume":"89","author":"Lichtman","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-012-9401-2","article-title":"Pharmacokinetics and tissue disposition of lenalidomide in mice","volume":"14","author":"Rozewski","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0295","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/cncr.22290","article-title":"Phase II study of lenalidomide in patients with metastatic renal cell carcinoma","volume":"107","author":"Choueiri","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0300","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1002\/cncr.24576","article-title":"Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma","volume":"115","author":"Glaspy","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","article-title":"Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma","volume":"116","author":"Eisen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0310","doi-asserted-by":"crossref","first-page":"e62264","DOI":"10.1371\/journal.pone.0062264","article-title":"Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer","volume":"8","author":"Siena","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0315","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0320","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0325","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/10428190802023707","article-title":"Azotemia associated with use of lenalidomide in plasma cell dyscrasias","volume":"49","author":"Batts","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0330","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","article-title":"Lenalidomide-induced acute interstitial nephritis","volume":"15","author":"Lipson","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0335","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1684\/ejd.2012.1853","article-title":"Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide","volume":"22","author":"Foti","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0340","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1078155213502569","article-title":"A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide","volume":"20","author":"Shaaban","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0345","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1592\/phco.31.9.925","article-title":"Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma","volume":"31","author":"Boruah","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0350","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s12185-012-1226-3","article-title":"Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone","volume":"96","author":"Shahan","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0355","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12185-011-0903-y","article-title":"Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin","volume":"94","author":"Urata","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0360","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.12391","article-title":"Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis","volume":"13","author":"Meyers","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0365","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.ajkd.2013.06.018","article-title":"Minimal change disease and lenalidomide","volume":"62","author":"Jamme","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0370","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0375","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","article-title":"Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects","volume":"69","author":"Chen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0380","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.2010.32.4962","article-title":"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein","volume":"29","author":"Hofmeister","year":"2011","journal-title":"J Clin Oncol"},{"year":"2007","series-title":"Revlemid (lenalidomide) [package insert]","key":"10.1016\/j.bulcan.2016.01.020_bib0385"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0390","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","article-title":"Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na\u00efve patients undergoing front-line lenalidomide and dexamethasone therapy","volume":"138","author":"Niesvizky","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s12032-009-9262-4","article-title":"Multiple myeloma: management of adverse events","volume":"27","author":"Gay","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0400","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"year":"2011","series-title":"Revlimid Capsules Package Insert","key":"10.1016\/j.bulcan.2016.01.020_bib0405"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0410","first-page":"1013","article-title":"Use of lenalidomide (Revlimid)\u00b1corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels (abstract)","volume":"108","author":"Reece","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0415","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0420","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0425","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0430","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00011","article-title":"Effect of dose intensive intravenous melphalan and autologous blood stem cell transplantation on al amyloidosis-associated renal disease","volume":"134","author":"Dember","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0435","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","article-title":"Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment","volume":"90","author":"Klein","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0440","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01432.x","article-title":"Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment","volume":"85","author":"Dimopoulos","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0450","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clml.2012.01.001","article-title":"Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers","volume":"12","author":"Oehrlein","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0455","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-0609.2010.01500.x","article-title":"Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study","volume":"85","author":"de la Rubia","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0460","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/10428190310001638841","article-title":"Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide","volume":"45","author":"Montagut","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0465","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/leu.2010.199","article-title":"A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL\/SLL","volume":"24","author":"Brown","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0470","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0475","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2008.06.001","article-title":"Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma","volume":"33","author":"van der Spek","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0480","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/thy.2006.0294","article-title":"Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma","volume":"17","author":"Stein","year":"2007","journal-title":"Thyroid"},{"issue":"suppl. 1","key":"10.1016\/j.bulcan.2016.01.020_bib0485","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: linking bench and clinical findings","volume":"24","author":"Davies","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0490","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0495","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft Lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0500","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5966\/sctm.2012-0115","article-title":"Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment","volume":"2","author":"Sung","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0505","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0510","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/01.TP.0000155179.61445.78","article-title":"Critical influence of natural regulatory CD25\u00fe T cells on the fate of allografts in the absence of immunosuppression","volume":"79","author":"Benghiat","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0515","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.TP.0000155178.20481.77","article-title":"Regulatory T cells in transplantation: natural or induced?","volume":"79","author":"Bolton","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.bulcan.2016.01.020_bib0260","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511600059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511600059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:16:57Z","timestamp":1748791017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511600059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S000745511600059X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.01.020","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phrotoxicit\u00e9 du l\u00e9nalidomide","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}